Impact of HIV-1 Envelope Conformation on ADCC Responses

Trends in Microbiology

Volumn 26, Issue 4, 2018, Pages 253-265

  Richard, Jonathan ^a,b   Prévost, Jérémie ^a,b   Alsahafi, Nirmin ^a,c   Ding, Shilei ^a,b   Finzi, Andrés ^a,b,c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

ADCC; CD4; envelope glycoproteins; HIV 1; Nef; Vpu

Indexed keywords

CD4 ANTIGEN; NEUTRALIZING ANTIBODY; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; KLRK1 PROTEIN, HUMAN; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CONFORMATIONAL TRANSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS TRANSMISSION; CD4+ T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4-POSITIVE T-LYMPHOCYTES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES, T-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; LIGANDS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN CONFORMATION; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 85034733206     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2017.10.007     Document Type: Review

References (130)

1. Antiretroviral Therapy Cohort Collaboration, Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372 (2008), 293–299.
2. Chun, T.W., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 (1997), 183–188.
3. Finzi, D., et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–1300.
4. Chomont, N., et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15 (2009), 893–900.
5. Rerks-Ngarm, S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361 (2009), 2209–2220.
6. Haynes, B.F., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366 (2012), 1275–1286.
7. Bonsignori, M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86 (2012), 11521–11532.
8. Kohl, S., Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev. Infect. Dis. 13 (1991), 108–114.
9. Beltran, D., Lopez-Verges, S., NK cells during Dengue disease and their recognition of Dengue virus-infected cells. Front. Immunol., 5, 2014, 192.
10. Jegaskanda, S., et al. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87 (2013), 5512–5522.
11. Kramski, M., et al. HIV-specific antibody immunity mediated through NK cells and monocytes. Curr. HIV Res. 11 (2013), 388–406.
12. Banks, N.D., et al. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18 (2002), 1197–1205.
13. Sun, Y., et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85 (2011), 6906–6912.
14. Alpert, M.D., et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog., 8, 2012, e1002890.
15. Baum, L.L., et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157 (1996), 2168–2173.
16. Forthal, D.N., et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180 (1999), 1338–1341.
17. Ljunggren, K., et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J. Infect. Dis. 161 (1990), 198–202.
18. Chung, A.W., et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 58 (2011), 127–131.
19. Mabuka, J., et al. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog., 8, 2012, e1002739.
20. Milligan, C., et al. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 17 (2015), 500–506.
21. Milligan, C., Overbaugh, J., The role of cell-associated virus in mother-to-child HIV transmission. J. Infect. Dis. 210:Suppl 3 (2014), S631–S640.
22. Reh, L., et al. Capacity of broadly neutralizing antibodies to inhibit HIV-1 Cell-Cell transmission is strain- and epitope-dependent. PLoS Pathog., 11, 2015, e1004966.
23. Smalls-Mantey, A., et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86 (2012), 8672–8680.
24. Dalgleish, A., et al. Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin. Exp. Immunol. 81 (1990), 5–10.
25. Koup, R.A., et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J. Virol. 63 (1989), 584–590.
26. Hessell, A.J., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
27. Dugast, A.S., et al. Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS One, 9, 2014, e97229.
28. Nakane, T., et al. Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. PLoS One, 8, 2013, e73453.
29. Moog, C., et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal. Immunol. 7 (2014), 46–56.
30. Astronomo, R.D., et al. Neutralization takes precedence over IgG or IgA isotype-related functions in mucosal HIV-1 antibody-mediated protection. EBioMedicine 14 (2016), 97–111.
31. Horwitz, J.A., et al. Non-neutralizing antibodies alter the course of HIV-1 infection in vivo. Cell, 170, 2017 637–648 e10.
32. Bradley, T., et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat. Commun., 8, 2017, 15711.
33. Allan, J.S., et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228 (1985), 1091–1094.
34. Robey, W.G., et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228 (1985), 593–595.
35. Wyatt, R., Sodroski, J., The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998), 1884–1888.
36. Alkhatib, G., et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996), 1955–1958.
37. Choe, H., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85 (1996), 1135–1148.
38. Deng, H., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996), 661–666.
39. Doranz, B.J., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996), 1149–1158.
40. Dragic, T., et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996), 667–673.
41. Feng, Y., et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996), 872–877.
42. Wu, L., et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996), 179–183.
43. Trkola, A., et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996), 184–187.
44. Furuta, R.A., et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5 (1998), 276–279.
45. Herschhorn, A., et al. Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins. MBio, 7, 2016 e01598–16.
46. Munro, J.B., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346 (2014), 759–763.
47. Veillette, M., et al. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J. Virol. 89 (2015), 545–551.
48. Kwon, Y.D., et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 5663–5668.
49. Liu, J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 455 (2008), 109–113.
50. Mao, Y., et al. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. Nat. Struct. Mol. Biol. 19 (2012), 893–899.
51. Kwong, P.D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998), 648–659.
52. Xiang, S.H., et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76 (2002), 9888–9899.
53. Finzi, A., et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37 (2010), 656–667.
54. Prevost, J., et al. Influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to antibody-dependent cell-mediated cytotoxicity responses. J. Virol., 91, 2017 e02452–16.
55. Schon, A., et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochemistry 45 (2006), 10973–10980.
56. Melillo, B., et al. Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. ACS Med. Chem. Lett. 7 (2016), 330–334.
57. Richard, J., et al. Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anti-cluster A ADCC epitopes on HIV-1 envelope glycoproteins. EBioMedicine 12 (2016), 208–218.
58. Richard, J., et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E2687–E2694.
59. Desormeaux, A., et al. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J. Virol. 87 (2013), 2549–2562.
60. Ding, S., et al. A highly conserved residue of the HIV-1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anti-cluster A antibodies. J. Virol. 90 (2015), 2127–2134.
61. Veillette, M., et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 88 (2014), 2633–2644.
62. Alvarez, R.A., et al. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J. Virol. 88 (2014), 6031–6046.
63. Arias, J.F., et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 6425–6430.
64. Pham, T.N., et al. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirology, 11, 2014, 15.
65. Lama, J., et al. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr. Biol. 9 (1999), 622–631.
66. Neil, S.J., et al. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008), 425–430.
67. Van Damme, N., et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 (2008), 245–252.
68. von Bredow, B., et al. Envelope glycoprotein internalization protects human and simian immunodeficiency virus infected cells from antibody-dependent cell-mediated cytotoxicity. J. Virol. 89 (2015), 10648–10655.
69. Alsahafi, N., et al. Nef proteins from HIV-1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity. J. Virol. 90 (2015), 2993–3002.
70. Cerboni, C., et al. Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J. Gen. Virol. 88:Pt 1 (2007), 242–250.
71. Parsons, M.S., et al. NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. AIDS Res. Hum. Retroviruses 32 (2016), 1089–1096.
72. Alsahafi, N., et al. Impaired downregulation of NKG2D ligands by Nef protein from elite controllers sensitizes HIV-1-infected cells to ADCC. J. Virol., 91, 2017 e00109–17.
73. Guan, Y., et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E69–E78.
74. Robinson, J.E., et al. Distinct antigenic sites on HIV gp120 identified by a panel of human monoclonal antibodies. J. Cell. Biochem., 449(Suppl. 16E), 1992, Q449.
75. Wyatt, R., et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69 (1995), 5723–5733.
76. Moore, J.P., et al. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68 (1994), 469–484.
77. Moore, J.P., et al. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 68 (1994), 6836–6847.
78. Acharya, P., et al. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J. Virol. 88 (2014), 12895–12906.
79. Tolbert, W.D., et al. Paring down HIV Env: design and crystal structure of a stabilized inner domain of HIV-1 gp120 displaying a major ADCC target of the A32 region. Structure 24 (2016), 697–709.
80. Ferrari, G., et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85 (2011), 7029–7036.
81. Bruel, T., et al. Lack of ADCC breadth of human non-neutralizing anti-HIV-1 antibodies. J. Virol., 91, 2017 e02440–16.
82. Richard, J., et al. BST-2 expression modulates small CD4-mimetic sensitization of HIV-1-infected cells to antibody-dependent cellular cytotoxicity. J. Virol., 91, 2017 e00219–17.
83. Richard, J., et al. Small CD4 mimetics prevent HIV-1 uninfected bystander CD4 + T cell killing mediated by antibody-dependent cell-mediated cytotoxicity. EBioMedicine 3 (2016), 122–134.
84. von Bredow, B., et al. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. J. Virol. 90 (2016), 6127–6139.
85. Mujib, S., et al. Comprehensive cross-clade characterization of antibody-mediated recognition, complement-mediated lysis, and cell-mediated cytotoxicity of HIV-1 envelope-specific antibodies toward eradication of the HIV-1 reservoir. J. Virol., 91, 2017 e00634–17.
86. Pham, T.N., et al. Enhancing virion tethering by BST2 sensitizes productively and latently HIV-infected T cells to ADCC mediated by broadly neutralizing antibodies. Sci. Rep., 6, 2016, 37225.
87. Bruel, T., et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun., 7, 2016, 10844.
88. Tomescu, C., et al. IFN-alpha augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation. AIDS 31 (2017), 613–622.
89. Falkowska, E., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40 (2014), 657–668.
90. Hessell, A.J., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15 (2009), 951–954.
91. Bournazos, S., et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
92. Veillette, M., et al. Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses. Curr. HIV Res. 14 (2016), 9–23.
93. Richard, J., et al. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J. Virol. Methods 208 (2014), 107–114.
94. Orlandi, C., et al. A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies. J. Immunol. Methods 433 (2016), 51–58.
95. Blattner, C., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40 (2014), 669–680.
96. Doria-Rose, N.A., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
97. Huang, J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515 (2014), 138–142.
98. Walker, L.M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
99. Julien, J.P., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog, 9, 2013, e1003342.
100. Thali, M., et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 66 (1992), 5635–5641.
101. Wu, X., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
102. Williams, K.L., et al. HIV-specific CD4-induced antibodies mediate broad and potent antibody-dependent cellular cytotoxicity activity and are commonly detected in plasma from HIV-infected humans. EBioMedicine 2 (2015), 1464–1477.
103. Pollara, J., et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79 (2011), 603–612.
104. Gomez-Roman, V.R., et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308 (2006), 53–67.
105. Tyler, D.S., et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J. Immunol. 144 (1990), 3375–3384.
106. Johansson, S.E., et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol. 24 (2011), 359–368.
107. Stratov, I., et al. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 82 (2008), 5450–5459.
108. Alpert, M.D., et al. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 86 (2012), 12039–12052.
109. Lewis, G.K., et al. Beyond viral neutralization. AIDS Res. Hum. Retroviruses 33 (2017), 760–764.
110. Asokan, M., et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. J. Virol. 89 (2015), 12501–12512.
111. Bournazos, S., et al. Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165 (2016), 1609–1620.
112. Galimidi, R.P., et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160 (2015), 433–446.
113. Mabondzo, A., et al. Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody. J. Gen. Virol. 75:Pt 6 (1994), 1451–1456.
114. Huang, Y., et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165 (2016), 1621–1631.
115. Pace, C.S., et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 13540–13545.
116. Bardhi, A., et al. Potent in vivo NK cell-mediated elimination of HIV-1-infected cells mobilized by a gp120-bispecific and hexavalent broadly neutralizing fusion protein. J. Virol., 91, 2017 e00937–17.
117. Chen, W., et al. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J. Virol. 88 (2014), 1125–1139.
118. Gardner, M.R., et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519 (2015), 87–91.
119. Lagenaur, L.A., et al. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology, 7, 2010, 11.
120. Sun, M., et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J. Acquir. Immune Defic. Syndr. 66 (2014), 473–483.
121. West, A.P. Jr., et al. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. J. Virol. 84 (2010), 261–269.
122. Liu, H., et al. Fc Engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front. Immunol., 8, 2017, 38.
123. Pegu, A., et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nat. Commun., 6, 2015, 8447.
124. Sloan, D.D., et al. Targeting HIV reservoir in infected CD4 T cells by Dual-Affinity Re-targeting Molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog., 11, 2015, e1005233.
125. Sung, J.A., et al. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125 (2015), 4077–4090.
126. Liu, L., et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J. Virol. 89 (2015), 6685–6694.
127. Decker, J.M., et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 201 (2005), 1407–1419.
128. Thali, M., et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67 (1993), 3978–3988.
129. Ding, S., et al. Short communication: small-molecule CD4 mimetics sensitize HIV-1-infected cells to antibody-dependent cellular cytotoxicity by antibodies elicited by multiple envelope glycoprotein immunogens in nonhuman primates. AIDS Res. Hum. Retroviruses 33 (2017), 428–431.
130. Madani, N., et al. Antibodies elicited by multiple envelope glycoprotein immunogens in primates neutralize primary human immunodeficiency viruses (HIV-1) sensitized by CD4-mimetic compounds. J. Virol. 90 (2016), 5031–5046.